Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02)
Phase of Trial: Phase I
Latest Information Update: 15 Jan 2018
At a glance
- Drugs CVA 21 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Viralytics
- 15 Dec 2009 Planned initiation date (Sep 2005) added as reported by Australian New Zealand Clinical Trials Registry record.
- 29 Sep 2007 New trial record.